{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:01:55Z","timestamp":1784739715982,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clinthera.2024.01.012","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T14:03:13Z","timestamp":1710511393000},"page":"444-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Impact of Vancomycin MIC on Outcomes in Patients With Coagulase-negative Staphylococcal Bacteremia"],"prefix":"10.1016","volume":"46","author":[{"given":"Wade","family":"Wheat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6087-5050","authenticated-orcid":false,"given":"Brenda","family":"Simiyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Andonie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Bellfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.01.012_bib0001","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1128\/CMR.00109-13","article-title":"Coagulase-negative staphylococci","volume":"27","author":"Becker","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.clinthera.2024.01.012_bib0002","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.00036-07","article-title":"From clinical microbiology to infection pathogenesis: how daring to be different works for Staphylococcus lugdunensis","volume":"21","author":"Frank","year":"2008","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.clinthera.2024.01.012_bib0003","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2024.01.012_bib0004","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/00365540701877304","article-title":"Prevalence and significance of coagulase-negative staphylococci isolated from blood cultures in a tertiary hospital","volume":"40","author":"Van Hal","year":"2008","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.clinthera.2024.01.012_bib0005","unstructured":"The Joint Commission. CLABSI Toolkit, https:\/\/www.jointcommission.org\/resources\/patient-safety-topics\/infection-prevention-and-control\/central-line-associated-bloodstream-infections-toolkit-and-monograph\/clabsi-toolkit\u2014introduction\/"},{"key":"10.1016\/j.clinthera.2024.01.012_bib0006","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1086\/320184","volume":"32","author":"Diekema","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.clinthera.2024.01.012_bib0007","first-page":"1143","article-title":"History and evolution of antibiotic resistance in coagulase-negative staphylococci: Susceptibility profiles of new anti-staphylococcal agents","volume":"3","author":"John","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clinthera.2024.01.012_bib0008","unstructured":"Lewis J, Weinstein M, et al. CLSI M100 -ED32\u202f:2022 Performance Standards for Antimicrobial Susceptibility Testing.32nd Edition 2022. Published Februaryhttps:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m100\/."},{"key":"10.1016\/j.clinthera.2024.01.012_bib0009","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.clinthera.2024.01.012_bib0010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1086\/524667","article-title":"Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Soriano","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2024.01.012_bib0011","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s100960000299","article-title":"Glycopeptide resistance in coagulase-negative staphylococci","volume":"19","author":"Biavasco","year":"2000","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2024.01.012_bib0012","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jinf.2015.02.007","article-title":"Coagulase-negative staphylococcal bloodstream infections: Does vancomycin remain appropriate empiric therapy?","volume":"71","author":"Valencia-Rey","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.clinthera.2024.01.012_bib0013","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1080\/23744235.2017.1323346","article-title":"Prognostic factors associated with 30-day in-hospital mortality in coagulase-negative Staphylococcus bacteraemia: no impact of vancomycin minimum inhibitory concentration","volume":"49","author":"Hentzien","year":"2017","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.clinthera.2024.01.012_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125818","article-title":"Epidemiology and prognosis of coagulase-negative staphylococcal endocarditis: impact of vancomycin minimum inhibitory concentration","volume":"10","author":"Garc\u00eda de la M\u00e0ria","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2024.01.012_bib0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12941-017-0238-5","article-title":"Vancomycin heteroresistance in coagulase negative Staphylococcus blood stream infections from patients of intensive care units in Mansoura University Hospitals, Egypt","volume":"16","author":"Mashaly","year":"2017","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.clinthera.2024.01.012_bib0016","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/jama.2018.13155","article-title":"Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial","volume":"320","author":"Holland","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2024.01.012_bib0017","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13756-019-0523-5","article-title":"The species distribution, antimicrobial resistance and risk factors for poor outcome of coagulase-negative staphylococci bacteraemia in China","volume":"8","author":"Cui","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.clinthera.2024.01.012_bib0018","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1086\/524666","article-title":"Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis","volume":"46","author":"Chu","year":"2008","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T18:29:51Z","timestamp":1726856991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824000213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0149291824000213"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.01.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Impact of Vancomycin MIC on Outcomes in Patients With Coagulase-negative Staphylococcal Bacteremia","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}